What changed
Edwards Lifesciences posted Q3 FY26 adjusted EPS of $0.80, beating the $0.73 consensus by $0.07 (+9.6%). Revenue came in at $1,716M, up 10.5% YoY (11.2% constant currency), with TAVR sales +8.0% to $1.24B and TMTT +44.0% to $207M. Management raised FY2026 adjusted EPS guidance to $2.97-$3.05 and Q4 FY26 adjusted EPS guidance to $0.61-$0.69. The beat was driven by better-than-expected topline performance and planned phasing of strategic investments in R&D and SG&A throughout the year.
Why it matters
Edwards Lifesciences posted Q3 FY26 adjusted EPS of $0.80, beating the $0.73 consensus by $0.07 (+9.6%). Revenue came in at $1,716M, up 10.5% YoY (11.2% constant currency), with TAVR sales +8.0% to $1